Jonathan S Zager, MD, FACS, FSSO

Articles by Jonathan S Zager, MD, FACS, FSSO

Expert Perspectives on BOLT clinical trial data

ByJonathan S Zager, MD, FACS, FSSO,Lilia Correa-Selm, MD, FAAD, FACMS,Aaron S. Farberg, MD,John Strasswimmer, MD, PhD,Andrew Weinstein, MD, FAAD

October 5th 2023

John Strasswimmer, MD, PhD comments on the impressive utility of both vismodegib and sonidegib in patients with advanced basal cell carcinoma and Jonathan S Zager, MD, FACS, FSSO provides his insight into the clinical utility of both of these treatments.

Data Review of 2 doses of Sonidegib in Advanced Basal Cell Carcinoma (BOLT Trial)

ByJonathan S Zager, MD, FACS, FSSO,Lilia Correa-Selm, MD, FAAD, FACMS,Aaron S. Farberg, MD,John Strasswimmer, MD, PhD,Andrew Weinstein, MD, FAAD

October 5th 2023

Jonathan S Zager, MD, FACS, FSSO reviews the clinical trial data relating to the BOLT study examining the use of sonidegib treatment in patients with locally advanced basal cell carcinoma, highlighting the critical differences in study design and data readouts between the BOLT and EVRIANCE trials.

Expert Perspectives on EVRIANCE clinical trial data

ByJonathan S Zager, MD, FACS, FSSO,Lilia Correa-Selm, MD, FAAD, FACMS,Aaron S. Farberg, MD,John Strasswimmer, MD, PhD,Andrew Weinstein, MD, FAAD

September 25th 2023

Andrew Weinstein, MD, MPH, FAAD and Jonathan S Zager, MD, FACS, FSSO explore the potential rationale behind observed variations in the and GLI and PTCH expression data within the EVRAINCE trial and comment on potential factors contributing to bias within the study.

Data Review of the Efficacy and Safety of Vismodegib in Advanced Basal Cell Carcinoma (EVRIANCE Trial)

ByJonathan S Zager, MD, FACS, FSSO,Lilia Correa-Selm, MD, FAAD, FACMS,Aaron S. Farberg, MD,John Strasswimmer, MD, PhD,Andrew Weinstein, MD, FAAD

September 25th 2023

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.